Top

Osteoporosis International

Published in:

01-03-2013 | Original Article

Sclerostin: a candidate biomarker of SCI-induced osteoporosis

Authors: L. R. Morse, S. Sudhakar, A. A. Lazzari, C. Tun, E. Garshick, R. Zafonte, R. A. Battaglino

Published in: Osteoporosis International | Issue 3/2013

Abstract

Summary

We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker.

Introduction

Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI.

Methods

We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI.

Results

After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002−0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18−0.99).

Conclusion

These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.

Szollar SM, Martin EM, Sartoris DJ, Parthemore JG, Deftos LJ (1998) Bone mineral density and indexes of bone metabolism in spinal cord injury. Am J Phys Med Rehabil 77(1):28–35PubMedCrossRef

Morse LR et al (2009) Osteoporotic fractures and hospitalization risk in chronic spinal cord injury. Osteoporos Int 20(3):385–392PubMedCrossRef

Morse LR et al (2009) VA-based survey of osteoporosis management in spinal cord injury. PM R 1(3):240–244PubMedCrossRef

Morse LR et al (2009) Dual energy X-ray absorptiometry of the distal femur may be more reliable than the proximal tibia in spinal cord injury. Arch Phys Med Rehabil 90(5):827–831PubMedCrossRef

Morse LR et al (2009) Barriers to providing dual energy X-ray absorptiometry services to individuals with spinal cord injury. Am J Phys Med Rehabil 88(1):57–60PubMedCrossRef

Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142(12):5050–5055PubMedCrossRef

Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69(3):990–1047PubMed

Patterson-Buckendahl P (2011) Osteocalcin is a stress-responsive neuropeptide. Endocr Regul 45(2):99–110PubMedCrossRef

Rosen HN et al (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66(2):100–103PubMedCrossRef

10.

Morse LR et al (2012) Association between sclerostin and bone density in chronic SCI. J Bone Miner Res Off J Am Soc Bone Miner Res 27(2):352–359CrossRef

11.

Garshick E et al (2005) A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord 43(7):408–416PubMedCrossRef

12.

Grandas NF et al (2005) Dyspnea during daily activities in chronic spinal cord injury. Arch Phys Med Rehabil 86(8):1631–1635PubMedCrossRef

13.

Kirshblum SC, Memmo P, Kim N, Campagnolo D, Millis S (2002) Comparison of the revised 2000 American Spinal Injury Association classification standards with the 1996 guidelines. Am J Phys Med Rehabil 81(7):502–505PubMedCrossRef

14.

Maimoun L et al (2002) Use of bone biochemical markers with dual-energy X-ray absorptiometry for early determination of bone loss in persons with spinal cord injury. Metabolism 51(8):958–963PubMedCrossRef

15.

Reiter AL, Volk A, Vollmar J, Fromm B, Gerner HJ (2007) Changes of basic bone turnover parameters in short-term and long-term patients with spinal cord injury. European Spine J: Off Publ Eur Spine Soc, Eur Spinal Deformity Soc, Eur Sect Cervical Spine Res Soc 16(6):771–776CrossRef

16.

Modder UI et al (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res: Off J Am Soc Bone Miner Res 26(2):373–379CrossRef

17.

Cejka D et al (2012) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 27(1):226–230CrossRef

18.

Drake MT et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062PubMedCrossRef

19.

Agholme F, Isaksson H, Kuhstoss S, Aspenberg P (2011) The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 48(5):988–996PubMedCrossRef

20.

Li X et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860–869PubMedCrossRef

21.

Lin C et al (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 24(10):1651–1661PubMedCrossRef

22.

MacDonald BT et al (2007) Bone mass is inversely proportional to Dkk1 levels in mice. Bone 41(3):331–339PubMedCrossRef

23.

Robling AG et al (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283(9):5866–5875PubMedCrossRef

24.

Robling AG, Bellido T, Turner CH (2006) Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6(4):354PubMed

25.

Li X et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883–19887PubMedCrossRef

26.

Mao B et al (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417(6889):664–667PubMedCrossRef

27.

Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing and Wnt signaling. Bone 42(4):606–615PubMedCrossRef

Title: Sclerostin: a candidate biomarker of SCI-induced osteoporosis
Authors: L. R. Morse
S. Sudhakar
A. A. Lazzari
C. Tun
E. Garshick
R. Zafonte
R. A. Battaglino
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2072-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sclerostin: a candidate biomarker of SCI-induced osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

The development of bone mineral lateralization in the arms

Sarcopenia and osteopenia among 70–80-year-old home-dwelling Finnish women: prevalence and association with functional performance

Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus

Sarcopenia prevalence: reply to comment by Perez-Zepeda et al

Effect of a multifactorial fall-and-fracture risk assessment and management program on gait and balance performances and disability in hospitalized older adults: a controlled study

Associations of vertebral deformities and osteoarthritis with back pain among Japanese women: the Hizen-Oshima study